As of November 10, 2026, Veraxa Biotech Holding AG is a publicly traded company (Nasdaq: VRXA). The largest holder reporting an active stake on Schedule 13D is Deck David Lukas, at 18%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, June 16, 2026).
Is this your company?
About to sign with, pay or invest in Veraxa Biotech Holding AG? See the free Snapshot first.
Free to see. No signup.
Is Veraxa Biotech Holding AG a real, registered company?
- Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp files with the SEC under CIK 2079109 (its SEC filings).
- Its shares are listed under the ticker VRXA on Nasdaq (also VRXAW) (SEC company record).
- Incorporated in V8, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names European Molecular Biology Laboratory (filed 2026-06-16).
Who are Veraxa Biotech Holding AG's owners and officers?
Veraxa Biotech Holding AG: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Aqr Capital Management, LLC | 0.46% |
| Schedule 13D, 2026-06-16 | European Molecular Biology Laboratory | 16.2% |
| Schedule 13D, 2026-06-16 | Deck David Lukas | 18% |
| Schedule 13D, 2026-06-15 | Schoeni Gilbert Edgar | 15.9% |
| Schedule 13D, 2026-06-15 | Xlife Sciences Ag | 16.3% |
Questions about who owns Veraxa Biotech Holding AG
Who owns Veraxa Biotech Holding AG?
On this page, 4 holders' latest ownership filings report 5% or more of Veraxa Biotech Holding AG: Deck David Lukas (18%, Schedule 13D, filed 2026-06-16), Xlife Sciences Ag (16.3%, Schedule 13D, filed 2026-06-15), European Molecular Biology Laboratory (16.2%, Schedule 13D, filed 2026-06-16) and Schoeni Gilbert Edgar (15.9%, Schedule 13D, filed 2026-06-15).
Who are the largest shareholders of Veraxa Biotech Holding AG?
By the share each holder's latest filing reports, the largest holders of Veraxa Biotech Holding AG on this page are Deck David Lukas (18%), Xlife Sciences Ag (16.3%) and European Molecular Biology Laboratory (16.2%).
When did Deck David Lukas buy into Veraxa Biotech Holding AG?
The filings give report dates, not purchase dates. The earliest filing from Deck David Lukas on this page is the Schedule 13D, filed 2026-06-16, reporting 18%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Veraxa Biotech Holding AG?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Veraxa Biotech Holding AG: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Veraxa Biotech Holding AG covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Veraxa Biotech Holding AG shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 5,773,618 shares, held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-08-31).
- , a director: 700,000 shares (Form 3, 2026-06-09).
- , a director: 37,932 shares (Form 4, 2026-10-21).
- , a director: 10,000 shares (Form 4, 2026-10-29).
- , the chief executive and a director: 5,000 shares (Form 4, 2026-08-31).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has Veraxa Biotech Holding AG raised?
Latest IPO step: Veraxa Biotech Holding AG amended its IPO registration (F-1/A, 2026-08-05).
IPO filings: F-1/A, 2026-08-05, F-1/A, 2026-08-05, F-1, 2026-07-31, F-1, 2026-07-31.
Keep reading
More on Veraxa Biotech Holding AG and the records around it.
Veraxa Biotech Holding AG elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/veraxa-biotech-holding-ag-f-k-a-voyager-acquisition